Drug Guidance for Subsidy 06/02/2026 Amivantamab for previously untreated, locally advanced or metastatic EGFR exon 20 insertion mutation-positive non-small-cell lung cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended amivantamab, in combina... See all × 06/02/2026 Amivantamab for previously untreated, locally advanced or metastatic EGFR exon 20 insertion mutation-positive non-small-cell lung cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended amivantamab, in combination with platinum-based chemotherapy for inclusion on the MOH List of Subsidised Drugs for previously untreated, locally advanced or metastatic epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive non-small-cell lung cancer. The decision was based on the uncertain extent of clinical benefit, unfavourable cost effectiveness compared with platinum-based chemotherapy, and the unacceptable price-volume agreement proposed by the company. Clinical indication, subsidy class and MediShield Life claim limit for amivantamab are provided in the Annex. 06/02/2026 Amivantamab for previously treated, locally advanced or metastatic EGFR exon 19 deletion or exon 21 L858R substitution mutation-positive non-small-cell lung cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended amivantamab, in combina... See all × 06/02/2026 Amivantamab for previously treated, locally advanced or metastatic EGFR exon 19 deletion or exon 21 L858R substitution mutation-positive non-small-cell lung cancer NRThe Ministry of Health’s Drug Advisory Committee has not recommended amivantamab, in combination with platinum-based chemotherapy, for inclusion on the MOH List of Subsidised Drugs for previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation-positive non-small-cell lung cancer. The decision was based on the uncertain extent of clinical benefit, unfavourable cost-effectiveness compared with platinum-based chemotherapy, and the unacceptable price-volume agreement proposed by the company. Clinical indication, subsidy class and MediShield Life claim limit for amivantamab are provided in the Annex.
INTRAVENOUS Select a brand starting with the letter: R RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML [SIN16548P]